Zymeworks ZYME 深 沪
等待开盘 10-06 09:30:00 美东时间
26.21
+1.060
+4.21%
华盛通- 最 高31.34
- 今 开25.37
- 成交量 60.42万股
- 最 低 25.04
- 昨 收 25.15
- 总市值 151.42万
- 52周最高 31.34
- 市盈率 静 --
- 换手率 1045.89%
- 52周最低 16.0034
- 委 比 24.52%
- 总股本 5.78万
- 历史最高 59.03
- 量 比 0.67
- 振 幅 25.05%
- 历史最低 1.10
- 每 手 1
- 风险率 2.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
09-29 01:05
Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est
Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million analyst estimate.
09-28 18:20
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final
09-28 18:12
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
06-29 21:20
Zymeworks Announces $125M Buyback Plan
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of
05-15 04:25
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
Earnings Breakdown: Zymeworks Q4
The Q4 earnings report for Zymeworks (NASDAQ:ZYME) was released on Monday, Marc...
03-02 19:06
Market-Moving News for November 17th
GOOG: 5% | Alphabet Inc shares are trading higher after Berkshire Hathaway disclosed a new stake in the company. ZYME: 61% | Zymeworks shares are trading higher after the company and its partners reported
2025-11-17 20:23
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
首款胃癌“国货之光”！石药/康宁杰瑞HER2双抗撬动百亿市场
（来源：求实药社） 2025年9月11日，石药集团与康宁杰瑞共同宣布，其合作开发的HER2双特异性抗体KN026（安尼妥单抗注射液）新药上市申请（NDA）已获中...
2025-09-16 12:05
